Foguth Wealth Management LLC. Invests $1.01 Million in CRISPR Therapeutics AG (NASDAQ:CRSP)

Foguth Wealth Management LLC. purchased a new position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 14,791 shares of the company’s stock, valued at approximately $1,008,000.

Several other hedge funds and other institutional investors have also made changes to their positions in CRSP. Blue Trust Inc. acquired a new position in CRISPR Therapeutics in the 4th quarter valued at about $32,000. Bourgeon Capital Management LLC increased its stake in shares of CRISPR Therapeutics by 1,000.0% during the 4th quarter. Bourgeon Capital Management LLC now owns 550 shares of the company’s stock valued at $34,000 after acquiring an additional 500 shares during the last quarter. NBC Securities Inc. increased its stake in shares of CRISPR Therapeutics by 257.6% during the 1st quarter. NBC Securities Inc. now owns 608 shares of the company’s stock valued at $41,000 after acquiring an additional 438 shares during the last quarter. Principal Securities Inc. acquired a new position in shares of CRISPR Therapeutics during the 4th quarter valued at about $41,000. Finally, TFC Financial Management Inc. increased its stake in shares of CRISPR Therapeutics by 3,400.0% during the 4th quarter. TFC Financial Management Inc. now owns 700 shares of the company’s stock valued at $44,000 after acquiring an additional 680 shares during the last quarter. Institutional investors and hedge funds own 69.20% of the company’s stock.

Insider Activity

In other news, COO Julianne Bruno sold 3,366 shares of CRISPR Therapeutics stock in a transaction dated Friday, June 21st. The stock was sold at an average price of $56.09, for a total transaction of $188,798.94. Following the completion of the sale, the chief operating officer now directly owns 6,745 shares in the company, valued at approximately $378,327.05. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, COO Julianne Bruno sold 3,366 shares of the business’s stock in a transaction that occurred on Friday, June 21st. The stock was sold at an average price of $56.09, for a total value of $188,798.94. Following the completion of the sale, the chief operating officer now directly owns 6,745 shares in the company, valued at approximately $378,327.05. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Samarth Kulkarni sold 19,582 shares of the business’s stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $59.91, for a total value of $1,173,157.62. Following the completion of the sale, the chief executive officer now owns 208,122 shares of the company’s stock, valued at $12,468,589.02. The disclosure for this sale can be found here. 4.10% of the stock is owned by corporate insiders.

CRISPR Therapeutics Stock Down 2.5 %

CRISPR Therapeutics stock traded down $1.37 during mid-day trading on Friday, hitting $54.01. The company’s stock had a trading volume of 1,313,469 shares, compared to its average volume of 1,370,108. The firm’s 50 day moving average is $56.72 and its 200 day moving average is $64.51. CRISPR Therapeutics AG has a 52-week low of $37.55 and a 52-week high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.35) by ($0.08). The company had revenue of $0.50 million during the quarter, compared to analysts’ expectations of $25.53 million. The company’s quarterly revenue was down 99.5% on a year-over-year basis. During the same period in the prior year, the company posted ($0.67) earnings per share. As a group, analysts expect that CRISPR Therapeutics AG will post -5.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

CRSP has been the subject of a number of research reports. Cantor Fitzgerald reiterated a “neutral” rating on shares of CRISPR Therapeutics in a report on Thursday, May 9th. Citigroup decreased their price target on CRISPR Therapeutics from $89.00 to $84.00 and set a “buy” rating for the company in a report on Thursday, May 23rd. Piper Sandler restated an “overweight” rating and issued a $105.00 price target on shares of CRISPR Therapeutics in a report on Monday, June 17th. JMP Securities restated a “market outperform” rating and issued a $86.00 price target on shares of CRISPR Therapeutics in a report on Thursday, May 9th. Finally, Guggenheim restated a “neutral” rating on shares of CRISPR Therapeutics in a report on Friday. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $75.71.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.